Combination therapy is also key to the treatment of metastatic colorectal cancer (CRC)-most frequently bearing KRAS, NRAS, BRAF, EGFR, and MYC mutations, loss of functions, amplifications, and microsatellite instability (MSI)-as reflected by ongoing clinical trials (e.g., HERACLES trial, NCT03225937) [18]. This evidence concerns the gene KRAS and metastatic colorectal cancer.